Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of novel immunotherapies with demonstrated success in haematological malignancies and melanoma. BiTEs developed for tumour associated antigens in prostate cancer have entered clinical testing. These trials have been hampered by high rates of treatment related adverse events, minimal or transient anti-tumour efficacy and generation of high titres of anti-drug antibodies. This paper aims to analyse the challenges faced by the different BiTE therapy constructs and the mCRPC tumour microenvironment that result in therapeutic resistance and identify possible strategies to overcome these issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By simultaneously binding to a tumor-associated antigen (TAA) on cancer cells and CD3 on T cells, BiTEs force an immunological synapse that facilitates T-cell activation, directed release of cytotoxic granules and cytokines, and ultimately targeted tumor cell lysis.”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In prostate cancer, PSMA is the most frequently targeted TAA due to its abundant expression on malignant cells, but other targets are currently being explored as well [26].”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“…with reduced metastatic burden, and has acted as an important proof of concept for immunotherapies outside of ICIs in prostate cancer treatment, sipuleucal-T has failed to be incorporated into routine treatment for mCRPC due to doubts about limited clinical bene fi t (Kantoff et al., 2010).”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“…(mCRPC) with ARSis, a broader range of chemotherapy agents, and Radium-223 radionucleotide treatment (Petrylak et al., 2004; de Bono et al., 2011; Parker et al., 2013; Beer et al., 2014; James et al., 2016; Fizazi et al., 2017; Kyriakopoulos et al., 2018; Armstrong et al., 2019; Chi et al.,…”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608 · cited 1×
“Immune checkpoint inhibitors (ICI) have revolutionised the management of a plethora of malignancies in the past decade (Robert, 2020).”
BackgroundApalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
(1997) · PubMed · Cited by 1,541
Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Armstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,104
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119115 · Cited by 977
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., Berthold, D., Ronchin, P., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00367-1 · Cited by 847
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Beer, T. M., Kwon, E. D., Drake, C. G., Fizazi, K., Logothetis, C., Gravis, G., Ganju, V., Polikoff, J., Saad, F., Humanski, P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1584 · Cited by 765
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Kazandjian, D., Suzman, D. L., Blumenthal, G., Mushti, S., He, K., Libeg, M., Keegan, P., & Pazdur, R. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0507 · Cited by 477
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., Wallmark, J. M., Keam, B., Delord, J.-P., Aggarwal, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy232 · Cited by 363
Self-citationRothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614636 · Cited by 337
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 282
Catumaxomab: Clinical development and future directions
Linke, R., Klein, A., & Seimetz, D. (2010) · mAbs · doi:10.4161/mabs.2.2.11221 · Cited by 274 · cited 1×
“…in trials of catumaxomab, an early example of a solid organ BiTE directed against epithelial cell adhesion molecule (EpCAM) and CD3 for EpCAM-positive advanced solid organ cancers causing malignant ascites, with one patient experiencing fatal acute fulminant liver failure (Linke et al., 2010).”
BackgroundGannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A.-M., & Saad, F. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.004 · Cited by 261
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
The landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 229
Eikenes, L., Tari, M., Tufto, I., Bruland, Ø. S., & de Lange Davies, C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602626 · Cited by 221
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Ge, R., Wang, Z., & Cheng, L. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00272-w · Cited by 192
Tosolini, M., Pont, F., Poupot, M., Vergez, F., Nicolau-Travers, M.-L., Vermijlen, D., Sarry, J. E., Dieli, F., & Fournié, J.-J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284723 · Cited by 191
Kebenko, M., Goebeler, M.-E., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1450710 · Cited by 177
Antonarakis, E. S., Shaukat, F., Isaacsson Velho, P., Kaur, H., Shenderov, E., Pardoll, D. M., & Lotan, T. L. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.009 · Cited by 177
Tabernero, J., Melero, I., Ros, W., Argiles, G., Marabelle, A., Rodriguez-Ruiz, M. E., Albanell, J., Calvo, E., Moreno, V., Cleary, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3002 · Cited by 170
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Middelburg, J., Kemper, K., Engelberts, P., Labrijn, A. F., Schuurman, J., & van Hall, T. (2021) · Cancers · doi:10.3390/cancers13020287 · Cited by 170
de Sostoa, J., Fajardo, C. A., Moreno, R., Ramos, M. D., Farrera-Sal, M., & Alemany, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0505-4 · Cited by 156
Hummel, H.-D., Kufer, P., Grüllich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M.-E., Miller, K., de Santis, M., Loidl, W., et al. (2021) · Immunotherapy · doi:10.2217/imt-2020-0256 · Cited by 154
Jawa, V., Terry, F., Gokemeijer, J., Mitra-Kaushik, S., Roberts, B. J., Tourdot, S., & De Groot, A. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01301 · Cited by 152
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0061 · Cited by 150
Friedrich, M., Raum, T., Lutterbuese, R., Voelkel, M., Deegen, P., Rau, D., Kischel, R., Hoffmann, P., Brandl, C., Schuhmacher, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0042 · Cited by 144
Engineering therapeutic bispecific antibodies using CrossMab technology
Klein, C., Schaefer, W., Regula, J. T., Dumontet, C., Brinkmann, U., Bacac, M., & Umaña, P. (2019) · Methods · doi:10.1016/j.ymeth.2018.11.008 · Cited by 143
Brünker, P., Wartha, K., Friess, T., Grau-Richards, S., Waldhauer, I., Koller, C. F., Weiser, B., Majety, M., Runza, V., Niu, H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0647 · Cited by 137
Belmontes, B., Sawant, D. V., Zhong, W., Tan, H. L. E., Kaul, A. M., Aeffner, F., O’Brien, S. A., Chun, M. G. H., Noubade, R., Eng, J. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1524 · Cited by 126
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0964 · Cited by 125
Herrmann, M., Krupka, C., Deiser, K., Brauchle, B., Marcinek, A., Wagner, A. O., Rataj, F., Mocikat, R., Metzeler, K. H., Spiekermann, K., et al. (2018) · Blood · doi:10.1182/blood-2018-05-849802 · Cited by 122
Therapeutic Antibodies against Intracellular Tumor Antigens
Trenevska, I., Li, D., & Banham, A. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01001 · Cited by 118
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
Ross, S. L., Sherman, M., McElroy, P. L., Lofgren, J. A., Moody, G., Baeuerle, P. A., Coxon, A., & Arvedson, T. (2017) · PLOS ONE · doi:10.1371/journal.pone.0183390 · Cited by 117
Pu, Y., Xu, M. M., Liang, Y., Yang, K., Guo, Y., Yang, X., & Fu, Y. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5659 · Cited by 111
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on.
Riethmüller, G. (2012) · Europe PMC (PubMed Central) · Cited by 107
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins
Jarvi, N. L., & Balu-Iyer, S. V. (2021) · BioDrugs · doi:10.1007/s40259-020-00465-4 · Cited by 105
Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 102
Deegen, P., Thomas, O., Nolan-Stevaux, O., Li, S., Wahl, J., Bogner, P., Aeffner, F., Friedrich, M., Liao, M. Z., Matthes, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3725 · Cited by 96
Krueger, T. E. G., Thorek, D. L. J., Meeker, A. K., Isaacs, J. T., & Brennen, W. N. (2018) · The Prostate · doi:10.1002/pros.23738 · Cited by 93
Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
Xu, Y.-R., Lee, J., Tran, C., Heibeck, T. H., Wang, W. D., Yang, J.-H., Stafford, R., Steiner, A. R., Sato, A., Hallam, T., et al. (2014) · mAbs · doi:10.4161/19420862.2015.989013 · Cited by 91
Geiger, M., Stubenrauch, K.-G., Sam, J., Richter, W. F., Jordan, G., Eckmann, J., Hage, C., Nicolini, V., Freimoser-Grundschober, A., Ritter, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16838-w · Cited by 91
Sharma, P., Pachynski, R. K., Narayan, V., Flechon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.142 · Cited by 88
On-target restoration of a split T cell-engaging antibody for precision immunotherapy
Banaszek, A., Bumm, T. G. P., Nowotny, B., Geis, M., Jacob, K., Wölfl, M., Trebing, J., Kucka, K., Kouhestani, D., Gogishvili, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13196-0 · Cited by 77
Kauer, J., Hörner, S., Osburg, L., Müller, S., Märklin, M., Heitmann, J. S., Zekri, L., Rammensee, H., Salih, H. R., & Jung, G. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000621 · Cited by 75
Hernandez-Hoyos, G., Sewell, T., Bader, R., Bannink, J., Chenault, R. A., Daugherty, M., Dasovich, M., Fang, H., Gottschalk, R., Kumer, J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0242 · Cited by 72
Shang, Z., Niu, Y., Cai, Q., Chen, J., Tian, J., Yeh, S., Lai, K.-P., & Chang, C. (2014) · Tumor Biology · doi:10.1007/s13277-013-1253-6 · Cited by 66
Panchal, A. P., Seto, P., Wall, R., Hillier, B. J., Zhu, Y. J., Krakow, J. L., Datt, A., Pongo, E., Bagheri, A., Chen, T.-H. T., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1792130 · Cited by 63
Xu, M., Evans, L., Bizzaro, C. L., Quaglia, F., Verrillo, C. E., Li, L., Stieglmaier, J., Schiewer, M. J., Languino, L. R., & Kelly, W. K. (2022) · Cancers · doi:10.3390/cancers14164034 · Cited by 61
An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
Zekri, L., Vogt, F., Osburg, L., Müller, S., Kauer, J., Manz, T., Pflügler, M., Maurer, A., Heitmann, J. S., Hagelstein, I., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911902 · Cited by 57
Nolan-Stevaux, O., Li, C., Liang, L., Zhan, J., Estrada, J., Osgood, T., Li, F., Zhang, H., Case, R., Murawsky, C. M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0984 · Cited by 55
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer
Simão, D. C., Zarrabi, K. K., Mendes, J. L., da Luz, R., Garcia, J. A., Kelly, W. K., & Barata, P. C. (2023) · Cancers · doi:10.3390/cancers15051412 · Cited by 52
Sun, B. L. (2021) · The Prostate · doi:10.1002/pros.24213 · Cited by 47
A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand
Lee, S. C., Ma, J. S. Y., Kim, M. S., Laborda, E., Choi, S., Hampton, E. N., Yun, H., Núñez, V., Muldong, M., Wu, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8193 · Cited by 42
De Bono, J. S., Fong, L., Beer, T. M., Gao, X., Geynisman, D. M., Burris III, H. A., Strauss, J. F., Courtney, K. D., Quinn, D. I., VanderWeele, D. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.5013 · Cited by 39
Penny, H. L., Hainline, K. M., Theoharis, N., Wu, B., Brandl, C., Webhofer, C., McComb, M., Wittemer‐Rump, S., Koca, G., Stienen, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261070 · Cited by 30
Maruta, M., Ochi, T., Tanimoto, K., Asai, H., Saitou, T., Fujiwara, H., Imamura, T., Takenaka, K., & Yasukawa, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49834-2 · Cited by 28
Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
Qin, C., Wang, J., Du, Y., & Xu, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1055826 · Cited by 28
Mehra, N., Robbrecht, D. G. J., Voortman, J., Parren, P. W. H. I., Maciá, S., Veeneman, J. M., Umarale, S., Winograd, B., van der Vliet, H. J., & Wise, D. R. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.6_suppl.153 · Cited by 21
Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R. R., Agarwal, N., Gulley, J. L., Attiyeh, E. F., Greger, J., Wu, S., Jaiprasart, P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.279 · Cited by 16
Self-citationSubudhi, S. K., Siddiqui, B. A., Maly, J. J., Nandagopal, L., Lam, E. T., Whang, Y. E., Minocha, M., Gupta, V., Penny, X., Cooner, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps5088 · Cited by 14
Aggarwal, R. R., Aparicio, A. M., Heidenreich, A., Sandhu, S. K., Zhang, Y., Salvati, M., Shetty, A., & Sadraei, N. H. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps5100 · Cited by 14
Buelow, B. D., Dalvi, P., Dang, K. H., Patel, A. P., Johal, K., Pham, D. T., Panchal, S., Liu, Y., Fong, L. H., Sartor, O. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps5092 · Cited by 9
Markowski, M. C., Kilari, D., Eisenberger, M. A., McKay, R. R., Dreicer, R., Trikha, M., Heath, E. I., Li, J., Garzone, P. D., & Young, T. S. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps5094 · Cited by 9
Pham, E., Lutterbuese, P., Deegen, P., Mariano, N. F., Matthes, K., Wahl, J., Bogner, P., Lane, J., Wilson, K. L., Yabut, R., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-nd06 · Cited by 9
Tran, B., Horvath, L. G., Rettig, M. B., Fizazi, K. S., Lolkema, M. P., Dorff, T. B., Greil, R., Machiels, J., Autio, K. A., Rottey, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.tps5590 · Cited by 7
Kelly, W. K., Thanigaimani, P., Sun, F., Seebach, F. A., Lowy, I., Sandigursky, S., & Miller, E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps5105 · Cited by 7
Heitmann, J. S., Walz, J. S., Pflügler, M., Marconato, M., Tegeler, C. M., Reusch, J., Labrenz, J., Schlenk, R. F., Jung, G., & Salih, H. R. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-ct141 · Cited by 7
Hackenbruch, C., Heitmann, J. S., Walz, J. S., Federmann, B., Pflügler, M., Hadaschik, B. A., Jung, G., & Salih, H. R. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.tps5114 · Cited by 6
Calvo, E., de Spéville, B. D., Galceran, J. C., Peer, A., Sarid, D. L., Eigl, B. J., Avadhani, A. N., Yao, D.-J., Lin, V., Wu, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.1499 · Cited by 4
Self-citationZhukovsky, E. A., Chu, S. Y., Bernett, M. J., Karki, S., Dang, W., Hammond, P. W., Edler, C., Polder, N., Chan, C., Jacinto, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3021 · Cited by 2
Lutterbuese, R., Friedrich, M., Kischel, R., Rau, D., Hoffmann, P., Ebert, E., Zopf, D., Finnern, R., Müeller, P. R., Baeuerle, P. A., et al. (2011) · Cancer Research · doi:10.1158/1538-7445.am2011-4561 · Cited by 1
Research works printed but not linked: 6
- 2010, Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection - guidelines for Industry
- Agency, 2017, Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins
- 2017, Aptevo therapeutics and MorphoSys end joint development and - commercialization agreement for mor209/es414
- 2022, Harpoon therapeutics reports fourth quarter and full year 2021 financial results and provides corporate update<harpoon-therapeutics-reports-fourth-quarter-and.pdf>
- 2019, Study with bispecific antibody engaging T-cells
- 2023, An interactive website for SEER cancer statistics: surveillance Research Program
Cited by
Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17071064 · Cited by 59
“Finally, dose-limiting toxicities—especially high-grade (grade 3/4) treatment-related adverse events—further complicate dose management and treatment continuation [72].”
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
“In prostate cancer, PSMA is the most frequently targeted TAA due to its abundant expression on malignant cells, but other targets are currently being explored as well [26].”
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Zhou, X., Hu, S., & Wang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101599 · Cited by 24
Khorasanchi, A., Hong, F., Yang, Y., Singer, E. A., Wang, P., Li, M., Zheng, L., Monk, P., Mortazavi, A., & Meng, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.173 · Cited by 39
Immune Checkpoint Inhibitor Therapy for Prostate Cancer: Present and Future Prospectives
Rai, V. (2025) · Biomolecules · doi:10.3390/biom15060751 · Cited by 18
Metadata
- Authors
- Lampe, H., Tam, L., & Hansen, A. R.
- Affiliations
- Queensland Health (AU)
- Corresponding author
- Hansen, Aaron R.
- ORCID
- Hansen, Aaron R.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-05-30
- Volume
- 15
- Pages
- 1399802-1399802
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC11169794
- OpenAlex
- W4399178517
- Cited by
- 21
- References
- 100
- Citations by year
- 2026: 6 · 2025: 15
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- bispecific T-cell engagers, metastatic castration-resistant prostate cancer, immunotherapy, tumor microenvironment, anti-drug antibodies, treatment-related adverse events, treatment resistance, tumor-associated antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.